[MOL] Re: [ANGIOGEN] FWD : Re: Judah Folkman [01935] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] Re: [ANGIOGEN] FWD : Re: Judah Folkman



For your info, Jeanne
>Date:         Sat, 14 Nov 1998 15:24:45 -0800
>Reply-To: "ANGIOGEN: Current Research on Angiogenesis"
<ANGIOGEN@LISTSERV.ACOR.ORG>
>Sender: "ANGIOGEN: Current Research on Angiogenesis"
<ANGIOGEN@LISTSERV.ACOR.ORG>
>From: Gene Valberg <genevalberg@YAHOO.COM>
>Subject:      Re: [ANGIOGEN] FWD : Re: Judah Folkman
>To: ANGIOGEN@LISTSERV.ACOR.ORG
>
>Gilles Frydman wrote:
>
>> Hello all,
>>
>> I am a scientist at a major biotech company working on various
>aspects of
>> cancer biology and treatment, including regulation of angiogenesis.
>It is
>
>Hey Gilles,
>
>Which university did you get your Ph.D. from and which bio-tech
>company are you working with ?
>
><snip>
>> and several anti-angiogenesis compounds are now going through clinical
>> trials. I would like to suggest that the audience should not
>overvalue the
>
>You are quite right in your evaluation and also correct about the
>trials. There are eighteen that I know of and I'll post them all below.
>
>Keep up the faith,
>
>Gene
>
>================== antiangiogenesis clinical trials ==================
>
> Drugs that prevent new blood vessels from invading surrounding tissue:
>
>- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
>Drug        Sponsor        Trial          Mechanism       For More Info
>
>Marimastat  British        Phase III      Synthetic MMP   800-355-6957
>            Biotech;       against        inhibitor
>            Annapolis, MD  pancreas, non
>                           small cell
>                           lung, breast
>                           cancers
>Bay 12-9566 Bayer; West    Phase III      Synthetic       800-442-4950
>            Haven, CT      against lung   inhibitor of
>                           and pancreatic tumor growth.
>                           cancers.
>AG3340      Agouron;       2 trials Ė     Synthetic MMP   888-849-6482
>            LaJolla, CA    Phase III      inhibitor
>                           against lung
>                           and against
>                           prostate
>                           cancers.
>MMI270      Novartis; East Phase I        Synthetic MMP   973-781-2791
>            Hanover, NJ                   inhibitor.
>COL-3       Collagenex;    Phase I        Synthetic MMP   800-4-CANCER
>            Newtown, PA/                  inihibitor.
>            NCI                           Tetracycline
>                                          derivative.
>Vitaxin     Ixsys, Inc.;   Phase II       Antibody to     619-597-4990
>            LaJolla, CA    enrollment     integrin,       x106
>                           will begin in  present on
>                           early-1999     endothelial
>                                          cell surface.
>
>
>
>                   Natural inhibitors of angiogenesis:
>- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
>Drug           Sponsor      Trial         Mechanism        For More Info
>
>Interleukin-12 Genetics     Phase I/II    Inhibits
>1-800-4-CANCER
>               Institute;                 endotheliel cell
>               Cambridge,                 growth
>               MA
>RhuMAb,        Genentech;   Phase II/III  Monoclonal       650-225-5300
>VEGF, and      South San    against lung, antibody to
>Anti-VEGF      Francisco,   breast,       vascular
>               CA           prostate,     endotheliel
>                            colorectal    growth factor
>                                          (VEGF)
>SU5416         Sugen, Inc.; Phase I and   Molecule that    650-306-7678
>               Redwood      Phase I/II    blocks VEGF
>               City, CA     for kaposiís  receptor
>                            sarcoma       signaling
>SU101          Sugen, Inc:  Phase III     Molecule         650-306-7678
>                            against       inhibitor that
>               Redwood      glioblastoma, blocks the
>               City, CA     and brain     signaling of the
>                            cancers.
>                            Phase II      platelet-derived
>                            against       growth factor
>                            glioblastoma, (PDGF) receptor.
>                            and Phase II
>                            against
>                            ovarian
>                            cancer.
>Interferon     Commercially Phase II/III  Molecule that
>1-800-4-CANCER
>-alfa          Available                  blocks VEGF
>                                          receptor
>                                          signaling
>
>           Interrupts function of dividing endothelial cells:
>- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
>Drug      Sponsor           Trial           Mechanism
>
>TNP-470   TAP               Phase II        Synthetic
>          Pharmaceuticals,  against         analogue of
>          Deerfield, IL     advanced cancer fungal protein;
>                            for adults with inhibits
>                            solid tumors.   endotheliel
>                                            cell growth
>
>Unknown mechanism; inhibits angiogenesis in laboratory and animal
>assays:
>- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
>Drug        Sponsor          Trial          Mechanism       For More
>
>Thalidomide Entremed, Inc.;  Phase II       Synthetic       301-217-9858
>            Rockville, MD    against        sedative
>                             Kaposiís
>                             sarcoma,
>                             breast,
>                             prostate and
>                             primary brain
>                             cancers
>CAI         NCI;             Phase II       Non-specific    800-4-CANCER
>            Bethesda, MD     against        inhibitor cell
>                             refractory or  invasion and
>                             recurrent      motility
>                             ovarian
>                             epitheliel,
>                             fallopian
>                             tube, and
>                             primary
>                             peritoneal
>                             cancer; Phase
>                             I against
>                             refractory,
>                             recurrent or
>                             advanced
>                             cancers
>Squalamine  Magainin         Phase I        Extract from    210-616-5798
>            Pharmaceuticals,                dogfish shark
>            Inc.; Plymouth                  liver; inhibits
>            Meeting, PA                     sodium-hydrogen
>                                            exchanger, NHE3
>IM862       Cytran;          Phase III      Unknown         425-889-5808
>            Kirkland, WA     trial against  mechanism
>                             AIDS-related
>                             Kaposiís
>                             sarcoma.
>                             Enrollment
>                             will begin in
>                             November.
>
>_________________________________________________________
>DO YOU YAHOO!?
>Get your free @yahoo.com address at http://mail.yahoo.com
>
>
------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------